ClinicalTrials.gov
public full text
Public Domain
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SGI-110 in Combination With Carboplatin in Ovarian Cancer#839915
- Neoadjuvant Therapy for Ovarian Cancer#898436
- Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer#1363818
- Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma#1364355
- Patient Selection Metrics and Efficacy of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Analysis.#330793
Record · ID 1214006
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive